|Articles|July 1, 2009

What Should Sponsors Ask Their IRB?

Accreditation, Previous Audits, Capacity, and Research Community Support All Factor Into Deciding on an Ethics Board

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

The CRA of the Future: From Monitoring Activity to Strategic Site Partnership

ByChi-Hui Tang, PhD

August 13th 2026

© Sergey Nivens - © Sergey Nivens - stock.adobe.com

Data Quality Across the Clinical Trial Lifecycle: What It Takes to Fully Trust Your Data

ByAndy Studna, Senior Editor

August 13th 2026

ACT Brief: Training Completion Versus Execution Readiness, AI Monitoring Agent Financial Value at Scale, and FDA Warning Letters and AI Oversight Gaps

ByAndy Studna, Senior Editor

August 13th 2026

Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program

ByAndy Studna, Senior Editor

August 12th 2026

Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work

ByOtis Johnson, PhD, MPA,Andy Studna, Senior Editor,Joseph Kim,Lauren Briggs

August 12th 2026

What Should Sponsors Ask Their IRB?

Related Content

The CRA of the Future: From Monitoring Activity to Strategic Site Partnership

Data Quality Across the Clinical Trial Lifecycle: What It Takes to Fully Trust Your Data

ACT Brief: Training Completion Versus Execution Readiness, AI Monitoring Agent Financial Value at Scale, and FDA Warning Letters and AI Oversight Gaps

Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program

Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work

Trending on Applied Clinical Trials Online

Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program

Breaking the Efficacy Ceiling in IBD and Beyond

Data Quality Across the Clinical Trial Lifecycle: What It Takes to Fully Trust Your Data

Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work

ACT Brief: Training Completion Versus Execution Readiness, AI Monitoring Agent Financial Value at Scale, and FDA Warning Letters and AI Oversight Gaps